• Globe Newswire

Callio Therapeutics to Present Phase 1 Trial Design of CLIO-8221, Novel Dual-Payload ADC, at ASCO 2026

Globenewswire -

• Globe Newswire

Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies

Globenewswire -

• Globe Newswire

Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics

Globenewswire -

• Globe Newswire

Hummingbird Bioscience Licenses Novel Antibodies to Immunome

Globenewswire -

• Globe Newswire

Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024